Selinexor in the treatment of liposarcoma: from preclinical evidence to clinical practice.

Selinexor is a new compound studied for the treatment of liposarcoma, particularly dedifferentiated liposarcoma (DDLPS), where treatment options remain limited. As a first-in-class oral exportin-1 (XPO1) inhibitor, selinexor has shown anti-tumour activity in preclinical models, particularly in MDM2- and CDK4-amplified DDLPS, where it induces apoptosis, inhibits tumour growth and promotes nuclear retention of p53. Preclinical studies have also suggested potential synergy with doxorubicin and eribulin, although these findings have yet to be validated in randomised clinical trials.

Can they blame it on the final? How does medical final exam and other factors shape specialty choice?

Background: Medical education in Poland consists of a six-year course, a 13-month postgraduate internship, and a Final Medical Examination. The possible further career path is to specialise in a particular field of medicine, and the choice of speciality is one of the most important decisions made by young doctors. Therefore, the decision-making process creates challenges.